MetaCap

Immunovant (IMVT) vs Twist Bioscience (TWST)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Twist Bioscience (TWST) has outperformed Immunovant (IMVT) over the past year, gaining 261.8% versus a gain of 40.6%. Over five years, IMVT leads with a +308.9% price change compared with +8.8% for TWST. Twist Bioscience is the larger company by market cap ($7.04 billion vs $6.57 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IMVT+40.64%TWST+261.76%
+649%+308%-34%
Nov 21, 20251 yearNov 20, 2026
IMVT+286.50%TWST-6.60%
+466%+175%-116%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IMVT versus TWST key metrics
MetricIMVTTWST
Share price$31.77$103.32
Market cap$6.57B$7.04B
1-day change-2.31%-7.44%
YTD return+24.98%+225.73%
1-year return+40.64%+261.76%
5-year return+308.88%+8.77%
EPS (TTM)$-2.56$-2.08
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$459.43M
Revenue growth (YoY)—+22.00%
Net income (latest FY)$-505.61M$-130.20M
Gross margin—52.41%
Operating margin—-30.35%
Net margin—-28.34%
52-week high$45.42$219.71
52-week low$21.93$28.27
Distance from 52-week high-30.05%-52.97%
Analyst consensusbuybuy
Avg. price target upside+53.07%+24.68%
Average volume1.42M2.49M
Shares outstanding206.95M68.18M
Employees3151,080
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TWST has outperformed IMVT by 221.1 percentage points over the past year.

About Immunovant

IMVT stock →

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 315 employees

About Twist Bioscience

TWST stock →

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; and Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, and other applications.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,080 employees

IMVT vs TWST FAQ

Which is bigger, Immunovant or Twist Bioscience?

Twist Bioscience (TWST) is larger, with a market capitalization of $7.04B compared with $6.57B for Immunovant (IMVT).

Which stock has performed better over the past year, IMVT or TWST?

TWST returned +261.76% over the past 12 months, compared with +40.64% for IMVT (price return, excluding dividends). Past performance does not predict future results.

Are Immunovant and Twist Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons